Dale Allison
Family Medicine · Waco, TXNPI 1154393429
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (55.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Novo Nordisk AS at 44.2% of the total. Reporting peaked in 2019 at $42,009 and has fallen 99.9% since, to $32 in 2025. Among family medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 114 payments — averaging $427.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$22K
- Novo Nordisk$20K
- CSL Behring$2K
- Alnylam Pharmaceuticals Inc.$2K
- Bayer$1K
- AbbVie$803
- plus $749 from 18 others
Across 3,502 payments — averaging $654.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$970K
- Alnylam Pharmaceuticals Inc.$297K
- AbbVie$277K
- CSL Behring$203K
- Sanofi US Services Inc.$188K
- AstraZeneca$143K
- plus $213K from 10 others
What the payments were for
- Consulting fees$18,44038%
- Speaking & faculty fees$6191%
- Travel & lodging$27,14656%
- Food & beverage$2,5155%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 13 | $21,550 |
| Novo Nordisk | 26 | $20,201 |
| CSL Behring | 11 | $2,392 |
| Alnylam Pharmaceuticals Inc. | 9 | $1,837 |
| Bayer | 2 | $1,220 |
| AbbVie | 5 | $803 |
| Dexcom, Inc. | 7 | $103 |
| Medtronic | 1 | $85 |
| AstraZeneca | 6 | $82 |
| GSK | 5 | $73 |
| Amarin Pharma, Inc. | 5 | $68 |
| Johnson & Johnson | 3 | $42 |
| Shire North American Group Inc | 3 | $39 |
| Merck | 3 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| Sunovion Pharmaceuticals Inc. | 2 | $34 |
| Amgen(2 entities) | 2 | $33 |
| Radius Health, Inc. | 2 | $26 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Pfizer | 1 | $15 |
| Genentech USA, Inc. | 1 | $12 |
| Lilly USA, LLC | 1 | $12 |
| Bausch Health US, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered$1,220
- UBRELVY$750
How this compares
$48,753 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Famotidine | 30 | $826 |
| Warfarin Sodium | 25 | $279 |
| Losartan Potassium | 13 | $237 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Waco
- Joshua StakeWaco$82K
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.